{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for phenobarbital in Any Name (approximate match)
Status:
US Approved Rx
(2022)
Source:
NDA215910
(2022)
Source URL:
First marketed in 1912
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels.
Status:
US Approved Rx
(2022)
Source:
NDA215910
(2022)
Source URL:
First marketed in 1912
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels.
Status:
US Approved Rx
(2022)
Source:
NDA215910
(2022)
Source URL:
First marketed in 1912
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels.
Status:
US Approved Rx
(2022)
Source:
NDA215910
(2022)
Source URL:
First marketed in 1912
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Phenobarbital is a barbiturate derivative used to treat insomnia and anxiety, seizures, hyperbilirubinemia in neonates and cholestasis. Phenobarbital promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels.
